The effects of cervical dilation on plasma PGFM, progesterone and the duration of luteal function in diestrous mares

• Published in: Theriogenology Vol. 32; no. 4; pp. 675 - 681
• Main Authors: Wilde, M.H., Dinger, J.E., Hoagland, T.A., Graves-Hoagland, R.L., Woody, C.O.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.1989
• Subjects: cervical dilation; CICLO ESTRAL; CYCLE OESTRAL; JUMENT; mare; MARES; OESTROUS CYCLE; PGF 2α; progesterone; PROSTAGLANDINAS; PROSTAGLANDINE; PROSTAGLANDINS; UTERO; UTERUS; YEGUA; mare; PGF 2α; progesterone; cervical dilation
• ISSN: 0093-691X; 1879-3231
• DOI: 10.1016/0093-691X(89)90288-4

Transcervical diagnostic techniques may alter the length of the equine estrous cycle and affect subsequent luteal function. Therefore, nine mares were used to determine the effect of cervical dilation on plasma 13, 14-dihydro, 15-keto-prostaglandin F 2 (PGFM), progesterone (P 4) and posttreatment duration of luteal function. Mares were given a daily score of 0 to 4 based on sexual receptivity. Five days following the end of receptivity, mares were randomly assigned to one of three, 3 × 3 latin squares. Control mares received no cervical dilation. Cervically stimulated mares recieved cervical dilation for 60 sec. Cervically stimulated plus inhibitor mares were dilated similarly to cervically stimulated mares, but received a prostaglandin synthetase inhibitor 30 min prior to treatment. Each mare completed all three treatments in three consecutive estrous cycles. Plasma PGFM and P 4 were determined by RIA. Plasma PGFM was lower (P<0.05) in cervically stimulated plus inhibitor than control and cervically stimulated mares. In addition, plasma P 4 was lower (P<0.10) in cervically stimulated plus inhibitor than in control and cervically stimulated mares. Luteal function following treatments did not differ. These data indicate that neither plasma PGFM and P 4 nor the duration of luteal function were affected by cervical dilation. However, administration of a prostaglandin synthetase inhibitor prior to cervical dilation decreased plasma PGFM and P 4 concentrations.